vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and DMC Global Inc. (BOOM). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $143.5M, roughly 1.3× DMC Global Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -7.8%, a 21.1% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -5.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $9.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -7.3%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
DMC Mining Services is a mining services contractor founded in 1980 operating in Canada, the United States, Chile, and Mongolia
AMPH vs BOOM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $143.5M |
| Net Profit | $24.4M | $-11.2M |
| Gross Margin | 46.8% | 17.1% |
| Operating Margin | 19.4% | -7.8% |
| Net Margin | 13.3% | -7.8% |
| Revenue YoY | -1.8% | -5.8% |
| Net Profit YoY | -35.7% | -3871.6% |
| EPS (diluted) | $0.51 | $-0.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $143.5M | ||
| Q3 25 | $191.8M | $151.5M | ||
| Q2 25 | $174.4M | $155.5M | ||
| Q1 25 | $170.5M | $159.3M | ||
| Q4 24 | $186.5M | $152.4M | ||
| Q3 24 | $191.2M | $152.4M | ||
| Q2 24 | $182.4M | $171.2M | ||
| Q1 24 | $171.8M | $166.9M |
| Q4 25 | $24.4M | $-11.2M | ||
| Q3 25 | $17.4M | $-3.1M | ||
| Q2 25 | $31.0M | $116.0K | ||
| Q1 25 | $25.3M | $677.0K | ||
| Q4 24 | $38.0M | $296.0K | ||
| Q3 24 | $40.4M | $-101.3M | ||
| Q2 24 | $37.9M | $4.0M | ||
| Q1 24 | $43.2M | $2.6M |
| Q4 25 | 46.8% | 17.1% | ||
| Q3 25 | 51.4% | 21.7% | ||
| Q2 25 | 49.6% | 23.6% | ||
| Q1 25 | 50.0% | 25.9% | ||
| Q4 24 | 46.5% | 20.8% | ||
| Q3 24 | 53.3% | 19.8% | ||
| Q2 24 | 52.2% | 27.1% | ||
| Q1 24 | 52.4% | 25.4% |
| Q4 25 | 19.4% | -7.8% | ||
| Q3 25 | 13.2% | 0.4% | ||
| Q2 25 | 24.2% | 2.5% | ||
| Q1 25 | 21.9% | 4.1% | ||
| Q4 24 | 24.2% | -0.5% | ||
| Q3 24 | 29.8% | -97.7% | ||
| Q2 24 | 30.3% | 6.8% | ||
| Q1 24 | 27.9% | 4.0% |
| Q4 25 | 13.3% | -7.8% | ||
| Q3 25 | 9.0% | -2.0% | ||
| Q2 25 | 17.8% | 0.1% | ||
| Q1 25 | 14.8% | 0.4% | ||
| Q4 24 | 20.4% | 0.2% | ||
| Q3 24 | 21.1% | -66.5% | ||
| Q2 24 | 20.8% | 2.3% | ||
| Q1 24 | 25.1% | 1.5% |
| Q4 25 | $0.51 | $-0.60 | ||
| Q3 25 | $0.37 | $-0.10 | ||
| Q2 25 | $0.64 | $-0.24 | ||
| Q1 25 | $0.51 | $0.04 | ||
| Q4 24 | $0.74 | $-0.18 | ||
| Q3 24 | $0.78 | $-8.27 | ||
| Q2 24 | $0.73 | $0.24 | ||
| Q1 24 | $0.81 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $31.9M |
| Total DebtLower is stronger | $608.7M | $50.6M |
| Stockholders' EquityBook value | $788.8M | $242.1M |
| Total Assets | $1.6B | $635.8M |
| Debt / EquityLower = less leverage | 0.77× | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $31.9M | ||
| Q3 25 | $276.2M | $26.4M | ||
| Q2 25 | $231.8M | $12.4M | ||
| Q1 25 | $236.9M | $14.7M | ||
| Q4 24 | $221.6M | $14.3M | ||
| Q3 24 | $250.5M | $14.5M | ||
| Q2 24 | $217.8M | $14.6M | ||
| Q1 24 | $289.6M | $20.4M |
| Q4 25 | $608.7M | $50.6M | ||
| Q3 25 | $608.6M | $56.5M | ||
| Q2 25 | $607.7M | $58.7M | ||
| Q1 25 | $603.9M | $72.4M | ||
| Q4 24 | $601.6M | $70.8M | ||
| Q3 24 | $596.4M | $74.2M | ||
| Q2 24 | $586.9M | $84.1M | ||
| Q1 24 | $594.0M | $88.0M |
| Q4 25 | $788.8M | $242.1M | ||
| Q3 25 | $776.7M | $253.0M | ||
| Q2 25 | $757.5M | $253.9M | ||
| Q1 25 | $751.3M | $253.9M | ||
| Q4 24 | $732.3M | $251.0M | ||
| Q3 24 | $727.7M | $256.5M | ||
| Q2 24 | $713.3M | $416.0M | ||
| Q1 24 | $672.4M | $409.9M |
| Q4 25 | $1.6B | $635.8M | ||
| Q3 25 | $1.7B | $644.1M | ||
| Q2 25 | $1.6B | $645.0M | ||
| Q1 25 | $1.6B | $670.6M | ||
| Q4 24 | $1.6B | $671.3M | ||
| Q3 24 | $1.5B | $702.0M | ||
| Q2 24 | $1.5B | $869.5M | ||
| Q1 24 | $1.6B | $860.0M |
| Q4 25 | 0.77× | 0.21× | ||
| Q3 25 | 0.78× | 0.22× | ||
| Q2 25 | 0.80× | 0.23× | ||
| Q1 25 | 0.80× | 0.29× | ||
| Q4 24 | 0.82× | 0.28× | ||
| Q3 24 | 0.82× | 0.29× | ||
| Q2 24 | 0.82× | 0.20× | ||
| Q1 24 | 0.88× | 0.21× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $15.2M |
| Free Cash FlowOCF − Capex | $24.6M | $9.6M |
| FCF MarginFCF / Revenue | 13.4% | 6.7% |
| Capex IntensityCapex / Revenue | 4.5% | 3.9% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $37.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $15.2M | ||
| Q3 25 | $52.6M | $18.6M | ||
| Q2 25 | $35.6M | $15.2M | ||
| Q1 25 | $35.1M | $4.5M | ||
| Q4 24 | $29.0M | $11.8M | ||
| Q3 24 | $60.0M | $19.0M | ||
| Q2 24 | $69.1M | $2.3M | ||
| Q1 24 | $55.3M | $13.4M |
| Q4 25 | $24.6M | $9.6M | ||
| Q3 25 | $47.2M | $14.4M | ||
| Q2 25 | $25.0M | $12.3M | ||
| Q1 25 | $24.4M | $709.0K | ||
| Q4 24 | $16.6M | $6.1M | ||
| Q3 24 | $46.2M | $12.9M | ||
| Q2 24 | $63.1M | $-204.0K | ||
| Q1 24 | $46.5M | $10.5M |
| Q4 25 | 13.4% | 6.7% | ||
| Q3 25 | 24.6% | 9.5% | ||
| Q2 25 | 14.3% | 7.9% | ||
| Q1 25 | 14.3% | 0.4% | ||
| Q4 24 | 8.9% | 4.0% | ||
| Q3 24 | 24.1% | 8.5% | ||
| Q2 24 | 34.6% | -0.1% | ||
| Q1 24 | 27.1% | 6.3% |
| Q4 25 | 4.5% | 3.9% | ||
| Q3 25 | 2.8% | 2.8% | ||
| Q2 25 | 6.1% | 1.9% | ||
| Q1 25 | 6.3% | 2.4% | ||
| Q4 24 | 6.7% | 3.7% | ||
| Q3 24 | 7.2% | 4.0% | ||
| Q2 24 | 3.3% | 1.5% | ||
| Q1 24 | 5.1% | 1.8% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 131.43× | ||
| Q1 25 | 1.39× | 6.63× | ||
| Q4 24 | 0.76× | 39.90× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 0.58× | ||
| Q1 24 | 1.28× | 5.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
BOOM
| Dyna Energetics Segment | $68.9M | 48% |
| Other | $57.0M | 40% |
| Nobel Clad Segment | $17.7M | 12% |
